Thirteen CCS patients in the OM-GHD group had IGF-1 levels < −2 SDS (48.1%), 11 patients had IGF-1 levels between −2 and 0 SDS (40.7%), and 3 patients had IGF-1 levels ≥0 SDS (11.1%). This evidence concerns the gene IGF1 and ocular melanoma.